This clinical trial is focused on studying a type of cancer called Unresectable Esophageal Squamous Cell Carcinoma. This is a condition where cancer cells form in the tissues of the esophagus, and the cancer cannot be removed by surgery. The study is testing the effectiveness of two treatments: Atezolizumab and Tiragolumab. Atezolizumab is a medication that helps the immune system attack cancer cells, while Tiragolumab is an experimental drug that may enhance the effects of Atezolizumab. Some participants will receive both Atezolizumab and Tiragolumab, while others will receive Atezolizumab with a placebo, or a double placebo.

The purpose of the study is to evaluate how well these treatments work in preventing the cancer from getting worse and in improving the overall survival of patients. Participants in the study will receive their treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will last for a period of up to 51 weeks, during which participants will be closely monitored by healthcare professionals. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo, to ensure unbiased results.

Throughout the study, participants will undergo regular check-ups and tests to assess their health and the progress of their cancer. The main goal is to see if the combination of Atezolizumab and Tiragolumab can help patients live longer and keep their cancer from progressing compared to those receiving the placebo. This study is an important step in finding more effective treatments for people with this type of esophageal cancer.